Pharmaceutical Executive August 2013

August 2013 | Volume 0, Issue 0
From the Editor
The trade media is ablaze with lurid accounts of bribery, tax fraud, and other illicit promotional activities in China—ironically, the country touted as guarantor of our industry's future.
Column
With a revision of China's basic drug approval law now underway, a multinational team of experts is proposing major changes to make the country a world class player in innovation.
The ?70 billion budget is still subject to final agreement on the European Union's overall spending plans for 2014-2020.
The best way to grow in the pharma industry is to think small.
Rate cuts and fraud concerns create problems for Part D plans and Part B providers.
In the spirit of lawn chair cogitation and hammock-spun reverie, Pharm Exec invites you to submit your own verses—pharma-related, of course—to be published on our website in late August.
Features
Shire's new CEO has a simple strategy for success: Set the pace on specialty medicines, spread the positive buzz and momentum of a growth stock, and seize the opportunity to innovate.
Reaching skittish consumers through objective, storydriven information is digital marketing's hottest digit. But applying this consumer phenomenon in Big Pharma presents some unique challenges, writes Peter Houston.
As growth in the BRICs and other emerging economies begins to stabilize, companies are finally turning their attention to Africa—a hidden trove of potential that is only as good as you make it.
Country Report
By Pharmaceutical Executive Editors
On the Northern fringes of Europe, those who want to believe that there is a sustainable future for the old continent's generous healthcare systems find a beacon of hope.
native1_300x100
lorem ipsum